Company news
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news
Karyopharm Therapeutics Inc. news releases on 6ix. Latest, Jul 14, 2020: Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO®…
Press releases — page 4
Karyopharm Announces Preliminary Unaudited Second Quarter Product Sales for XPOVIO® (selinexor)
July 13, 2020
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology
June 23, 2020
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
June 21, 2020
Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma
June 8, 2020
Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program
May 25, 2020
Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy
May 19, 2020
Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society
May 12, 2020
Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program
April 28, 2020
Karyopharm to Report First Quarter 2020 Financial Results on May 5, 2020
April 27, 2020
Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19
April 19, 2020
Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
March 16, 2020
Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer
March 11, 2020
Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
March 5, 2020
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
March 2, 2020
Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock
March 1, 2020
Karyopharm Appoints Richard Paulson to its Board of Directors
February 27, 2020
U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
February 18, 2020
Karyopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO® (Selinexor) in Israel
February 10, 2020
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 2, 2020
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
January 12, 2020
Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO® (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
December 22, 2019
Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting
December 6, 2019
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting
November 5, 2019
Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress
November 3, 2019
Karyopharm to Report Third Quarter 2019 Financial Results on November 4, 2019
October 27, 2019
Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 Million
September 15, 2019
Karyopharm Announces XPOVIO™ (Selinexor) Presentations at the 17th International Myeloma Workshop
September 12, 2019